drugset / Trial / NCT03764553
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer
Phase 2
Active not recruiting
320 enrolled
Academic Medical Center - University of Amsterdam
Servier · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, open label, randomized phase II trial for patients with previously untreated metastatic or locally advanced esophagogastric cancer, using a pick the winner design to identify the best combination therapy in terms of progression free survival and neurotoxicity.
Timeline
- Start
- 2019-05-01
- Primary completion
- 2025-07-31
- Completion
- 2026-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | IRINOTECAN | Small molecule | 80 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |